On estimation of overall treatment effects in multiregional clinical trials under a discrete random effects model.

Multiregional clinical trials (MRCTs) have become a standard strategy for pharmaceutical product development worldwide. The heterogeneity of regional treatment effects is anticipated in an MRCT. For a two-group comparative study in an MRCT, patient assignments, including regional weights and treatment allocation ratios, are predetermined under the same protocol.